Company Overview - Dexcom manufactures devices for diabetes patients with operations in Malaysia, Ireland, and Arizona [1] - The company has a significant US platform, including R&D and manufacturing [3] Financial Performance & Market Focus - Dexcom experienced a strong second quarter with 15% revenue growth, exceeding operating margin expectations [4] - The company remains strong in type 1 diabetes but is expanding into the type 2 diabetes market, targeting 25 million people in the US not on insulin [6][7] - Three largest PBMs now cover people with type two diabetes not on insulin, which is a great growth segment for Dexcom [8] Tariff & Supply Chain - Dexcom sources subcomponents from Mexico and chips for sensors from other countries [9] - The company is not concerned about tariffs as a cost driver and does not plan to increase prices for end users [10] - Worst-case tariff scenario would involve huge tariffs on components, but the company does not foresee this [11] Leadership Transition - The CEO will be stepping down at the end of the year, which surprised some investors [5]